[1]CurrentPatentAssignee:GILEADSCIENCESINC-WO2020/172075,2020,A1Locationinpatent:Paragraph0315;0323;0337
[2]CurrentPatentAssignee:GILEADSCIENCESINC-WO2020/185686,2020,A1Locationinpatent:Paragraph0290
[1]CurrentPatentAssignee:GILEADSCIENCESINC-WO2020/172075,2020,A1Locationinpatent:Paragraph0339
Title: Trauner M, et al. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
Title: Patel K, et al. Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 Mar 1.
Title: P. Schwab, et al. The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH. April 2018,Volume 68, Supplement 1, Pages S471-S472.